As conflict intensifies, women endure trauma, unsafe childbirth and heightened risks of exploitation and abuse daily.
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...